KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Divestments (2016 - 2023)

Historic Divestments for Novartis Ag (NVS) over the last 11 years, with Q4 2023 value amounting to -$738.0 million.

  • Novartis Ag's Divestments fell 39864.86% to -$738.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.1 billion, marking a year-over-year decrease of 33359.07%. This contributed to the annual value of -$88.0 million for FY2025, which is 18224.3% down from last year.
  • According to the latest figures from Q4 2023, Novartis Ag's Divestments is -$738.0 million, which was down 39864.86% from -$208.0 million recorded in Q3 2023.
  • In the past 5 years, Novartis Ag's Divestments registered a high of $6.0 million during Q3 2021, and its lowest value of -$738.0 million during Q4 2023.
  • For the 5-year period, Novartis Ag's Divestments averaged around -$148.6 million, with its median value being -$70.5 million (2019).
  • As far as peak fluctuations go, Novartis Ag's Divestments surged by 13000.0% in 2021, and later tumbled by 236666.67% in 2022.
  • Novartis Ag's Divestments (Quarter) stood at -$57.0 million in 2019, then surged by 96.49% to -$2.0 million in 2020, then tumbled by 200.0% to -$6.0 million in 2021, then crashed by 2366.67% to -$148.0 million in 2022, then crashed by 398.65% to -$738.0 million in 2023.
  • Its Divestments was -$738.0 million in Q4 2023, compared to -$208.0 million in Q3 2023 and -$93.0 million in Q2 2023.